Oncology Central

Capivasertib may be an effective treatment for patients with tumors with AKT mutations


In a recent Phase II trial researchers have discovered that capivasertib, an AKT inhibitor, may be an effective treatment for tumors with the AKT mutation. This research was carried out as part of a larger study taking place in the USA (NCI-MATCH) investigating molecular profiling of tumors and personalized treatments based upon specific genetic mutations rather than the traditional approach of treating cancer based on type.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.